Related Experiment Video
Updated: Jul 6, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Switching of hypertrophic signalling towards enhanced cardiomyocyte identity and maturity by a GATA4-targeted
Lotta Pohjolainen1, Sini M Kinnunen1, Samuli Auno2
1Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.
Insights
A novel compound, 3i-1262, promotes the maturation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This compound modulates cardiac transcription factors, enhancing cardiomyocyte identity and maturity for potential heart failure treatments.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Drug Discovery
Background:
- Increasing heart failure prevalence necessitates novel therapeutic strategies.
- Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are valuable in vitro models but exhibit immaturity.
- Immature hiPSC-CMs resemble fetal cardiomyocytes, limiting their utility for studying adult heart conditions.
Purpose of the Study:
- To develop and screen novel compounds for their ability to modulate cardiac function.
- To investigate the effects of a lead compound on cardiomyocyte hypertrophy and maturation.
- To understand the molecular mechanisms underlying compound-induced changes in hiPSC-CMs.
Main Methods:
- Synthesis and screening of 14 novel compounds for GATA4-NKX2-5 reporter activity and toxicity.
- Selection of compound 3i-1262 for further studies on induced hypertrophy models.
- Assessment of morphological changes, protein expression, and gene expression using immunofluorescence, high-content analysis, qPCR, and RNA sequencing.
Main Results:
- Compound 3i-1262 inhibited GATA4-NKX2-5 synergy and reduced the hypertrophy biomarker B-type natriuretic peptide (BNP).
- 3i-1262 treatment increased metabolic activity and cardiac troponin T expression in hiPSC-CMs.
- RNA sequencing revealed that 3i-1262 promotes gene expression related to metabolic activity and cell cycle exit, indicating enhanced maturity.
Conclusions:
- Compound 3i-1262 effectively promotes hiPSC-CM maturation by reorganizing the cardiac transcription factor network.
- This approach converts hypertrophic signaling towards enhanced cardiomyocyte identity and maturity.
- The compound provides a novel scaffold for developing therapies to improve cardiomyocyte specification and maturity.
Background:
The prevalence of heart failure is constantly increasing, and the prognosis of patients remains poor. New treatment strategies to preserve cardiac function and limit cardiac hypertrophy are therefore urgently needed. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used as an experimental platform for cardiac in vitro studies. However, in contrast to adult cardiomyocytes, hiPSC-CMs display immature morphology, contractility, gene expression and metabolism and hence express a naive phenotype that resembles more of a foetal cardiomyocyte.
Methods:
A library of 14 novel compounds was synthesized in-house and screened for GATA4-NKX2-5 reporter activity and cellular toxicity. The most potent compound, 3i-1262, along with previously reported GATA4-acting compounds, were selected to investigate their effects on hypertrophy induced by endothelin-1 or mechanical stretch. Morphological changes and protein expression were characterized using immunofluorescence staining and high-content analysis. Changes in gene expression were studied using qPCR and RNA sequencing.
Results:
The prototype compound 3i-1262 inhibited GATA4-NKX2-5 synergy in a luciferase reporter assay. Additionally, the isoxazole compound 3i-1262 inhibited the hypertrophy biomarker B-type natriuretic peptide (BNP) by reducing BNP promoter activity and proBNP expression in neonatal rat ventricular myocytes and hiPSC-CMs, respectively. Treatment with 3i-1262 increased metabolic activity and cardiac troponin T expression in hiPSC-CMs without affecting GATA4 protein levels. RNA sequencing analysis revealed that 3i-1262 induces gene expression related to metabolic activity and cell cycle exit, indicating a change in the identity and maturity status of hiPSC-CMs. The biological processes that were enriched in upregulated genes in response to 3i-1262 were downregulated in response to mechanical stretch, and conversely, the downregulated processes in response to 3i-1262 were upregulated in response to mechanical stretch.
Conclusions:
There is currently a lack of systematic understanding of the molecular modulation and control of hiPSC-CM maturation. In this study, we demonstrated that the GATA4-interfering compound 3i-1262 reorganizes the cardiac transcription factor network and converts hypertrophic signalling towards enhanced cardiomyocyte identity and maturity. This conceptually unique approach provides a novel structural scaffold for further development as a modality to promote cardiomyocyte specification and maturity.
More Related Videos
10:05Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
09:29Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
Published on: March 22, 2017
Related Concept Videos
TGF - β Signaling Pathway
Forced Transdifferentiation
Artificial...